World Clinical Drugs, Volume. 46, Issue 7, 724(2025)
Research progress of traditional Chinese medicine polysaccharide regulating intestinal flora in the treatment of non-alcoholic fatty liver disease
[1] [1] ZHANG W, CHENG W, LI J,et al. New aspects characterizing non-obese NAFLD by the analysis of the intestinal flora and metabolites using a mouse model [J]. mSystems, 2024, 9(3): e0102723.
[2] [2] SAFARI Z, GERARD P. The links between the gut microbiome and non-alcoholic fatty liver disease(NAFLD)[J]. Cell Mol Life Sci, 2019, 76(8): 1541-1558.
[3] [3] ALISI A, CECCARELLI S, PANERA N,et al. Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis [J]. Front Cell Infect Microbiol, 2012, 2: 132.
[4] [4] QUESADA-VAZQUEZ S, ARAGONES G, DEL BAS JM,et al. Diet, gut microbiota and non-alcoholic fatty liver disease: three parts of the same axis [J]. Cells, 2020, 9 (1): 176
[5] [5] HUANG F, LYU B, XIE F,et al. From gut to liver: unveiling the differences of intestinal microbiota in NAFL and NASH patients[J]. Front Microbiol, 2024, 15: 1366744.
[6] [6] DEL CHIERICO F, NOBILI V, VERNOCCHI P,et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated metaomics-based approach [J]. Hepatology, 2017, 65(2): 451-464.
[7] [7] HIGARZA SG, ARBOLEYA S, ARIAS JL,et al. The gut-microbiota-brain changes across the liver disease spectrum[J]. Front Cell Neurosci, 2022, 16: 994404.
[8] [8] ARON-WISNEWSKY J, VIGLIOTTI C, WITJES J,et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(5): 279-297.
[9] [9] JENNISON E, BYRNE CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease [J]. Clin Mol Hepatol, 2021, 27 (1): 22-43.
[10] [10] ABENAVOLI L, SCARLATA GGM, SCARPELLINI E,et al. Metabolic-dysfunction-associated fatty liver disease and gut microbiota: from fatty liver to dysmetabolic syndrome [J]. Medicina(Kaunas), 2023, 59 (3): 594.
[11] [11] ALBILLOS A, DE GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy [J]. J Hepatol, 2020, 72 (3): 558-577.
[12] [12] YE H, MA S, QIU Z,et al.Poria cocospolysaccharides rescue pyroptosis-driven gut vascular barrier disruption in order to alleviates non-alcoholic steatohepatitis [J]. J Ethnopharmacol, 2022, 296: 115457.
[13] [13] CHEN J, VITETTA L. Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications[J]. Int J Mol Sci,2020, 21 (15): 5214.
[14] [14] SHEN SH, ZHONG TY, PENG C,et al. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease withGynostemmapentaphyllumin rats[J]. Bio Med Central Complement Med Ther, 2020,20(1): 34
[15] [15] YUE SR, TAN YY, ZHANG L,et al.Gynostemma pentaphyllumpolysaccharides ameliorate non-alcoholic steatohepatitis in mice associated with gut microbiota and the TLR2/NLRP3 pathway [J]. Front Endocrinol (Lausanne),2022, 13: 885039.
[16] [16] HAO P, YANG X, YIN W,et al. A study on the treatment effects ofCrataegus pinnatifidapolysaccharide on non-alcoholic fatty liver in mice by modulating gut microbiota [J]. Front Vet Sci, 2024, 11: 1383801.
[17] [17] ZHANG Y, YANG L, ZHAO N,et al.Solublepolysaccharide derived from laminaria japonica attenuates obesity-related nonalcoholic fatty liver disease associated with gut microbiota regulation [J]. Mar Drugs, 2021, 19(12): 699.
[18] [18] ZHANG L, WANG Y, WU F,et al. MDG, anOphiopogon japonicuspolysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila[J]. Int J Biol Macromol, 2022, 196: 23-34.
[19] [19] Wang X, Shi L, Wang X,et al. MDG-1, anOphiopogonpolysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis [J]. Int J Biol Macromol, 2019, 141: 1013-1021.
[21] [21] HONG Y, SHENG L, ZHONG J,et al. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice [J]. Gut Microbes,2021, 13(1): 1-20
[22] [22] GAO LL, MA JM, FAN YN,et al.Lycium barbarumpolysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation [J]. Int J Biol Macromol, 2021, 183: 1379-1392.
[23] [23] YUAN Y, CHE L, QI C,et al. Protective effects of polysaccharides on hepatic injury: a review [J]. Int J Biol Macromol, 2019, 141: 822-830.
[24] [24] XIAO J, WANG F, LIONG EC,et al.Lycium barbarumpolysaccharides improve hepatic injury through NF-B and NLRP3/6 pathways in a methionine choline deficient diet steatohepatitis mouse model [J]. Int J Biol Macromol, 2018,120 (Pt B): 1480-1489.
[25] [25] LI DD, MA JM, LI MJ,et al. Supplementation ofLycium barbarumpolysaccharide combined with aerobic exercise ameliorates high-fat-induced nonalcoholic steatohepatitis via AMPK/PPAR/PGC-1 pathway [J]. Nutrients, 2022,14(15): 3247.
[27] [27] LI X, LING Y, HUANG X,et al.Rosa roxburghiitratt fruit extract prevents dss-induced ulcerative colitis in mice by modulating the gut microbiota and the IL-17 signaling pathway [J]. Nutrients, 2023, 15 (21): 4560.
[29] [29] ZHU L, XIAO M, LUO J,et al. Polysaccharides fromOstrea rivularisrebuild the balance of gut microbiota to ameliorate non-alcoholic fatty liver disease in ApoE-/- mice[J]. Int J Biol Macromol, 2023, 235: 123853.
[30] [30] LAN T, WU J, TANG B,et al. Fufang Zhenzhu Tiaozhi polysaccharides ameliorates high-fat diet-induced non-alcoholic steatohepatitis and intestinal flora disorders in mice [J]. J Funct Foods, 2024, 117: 106247.
[31] [31] LI TT, HUANG ZR, JIA RB,et al.Spirulina platensispolysaccharides attenuate lipid and carbohydrate metabolism disorder in high-sucrose and high-fat diet-fed rats in association with intestinal microbiota[J]. Food Res Int,2021, 147: 110530.
[32] [32] LI Q, LIU W, ZHANG H,et al. -D-1, 3-glucan from Radix Puerariae Thomsonii improves NAFLD by regulating the intestinal flora and metabolites [J]. Carbohydr Polym, 2023,299: 120197.
[33] [33] YANG X, YAO S, JIANG Q,et al. Exploring the regulatory effect ofTegillarca granosapolysaccharide on high-fat diet-induced non-alcoholic fatty liver disease in mice based on intestinal flora[J]. Mol Nutr Food Res, 2024, 68(14): e2300453.
[34] [34] HU Y, YIN F, LIU Z,et al. Acerola polysaccharides ameliorate high-fat diet-induced non-alcoholic fatty liver disease through reduction of lipogenesis and improvement of mitochondrial functions in mice[J]. Food Funct, 2020,11(1): 1037-1048.
Get Citation
Copy Citation Text
ZHANG Fengsen, GAN Xieyu, HE Chunyuan, ZHAO Weichen, WANG Fang, WANG Facai. Research progress of traditional Chinese medicine polysaccharide regulating intestinal flora in the treatment of non-alcoholic fatty liver disease[J]. World Clinical Drugs, 2025, 46(7): 724
Category:
Received: Jan. 9, 2025
Accepted: Aug. 26, 2025
Published Online: Aug. 26, 2025
The Author Email: